Research Review: FDA Breakthrough Device Designation for Revita in Weight Maintenance After GLP-1 Discontinuation

Promising research has emerged on a device that helps people maintain weight loss after stopping GLP-1 agonist drugs. Revita is a product that resurfaces the lining of the duodenum, potentially addressing the root cause of metabolic disease.

The duodenum is the first section of the small intestine which is in charge of breaking down food from the stomach and absorbing vitamins and minerals such as iron, calcium, phosphorus, biotin, folate, fat soluble vitamins, and more.

When diets are high in fat and sugar the lining of the duodenum is damaged causing a thickening. High fat and high sugar diets have been linked to an increase in damage and subsequently an increase in weight, negative behavior changes related to depression and anxiety, and insulin resistance.

The GLP-1 agonists such as Wegovy, Ozempic, and Zepbound are becoming very popular tools for weight loss, however they do not address the root causes of weight gain and diabetes. After weight loss the changes to the duodenal lining remain which increases the risk of weight regain.

Revita is an endoscopic procedure that looks at correcting the duodenal thickening by resurfacing and editing the abnormal nutrient sensing and signaling mechanisms that could be part of the root cause in metabolic disease. This resurfacing is believed to correct the bodies metabolism and blood glucose regulation. If this is paired with diet education we could have an effective sequence to correcting obesity and maintaining weight loss along with better control of metabolic diseases.

Clinical trials are still underway in both the US and Europe with potential for initial data results in the end of 2024 to mid 2025, so stay tuned.

References-